NCT05180292

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Institute of Liver and Biliary Sciences, India · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Various parameters will be assessed during the procedure before and after 1 hour of 12.5 mg carvedilol such as HVPG (WHVP - FHVP), SVR, heart rate, cardiac output, cardiac index, Blood pressure (systolic, diastolic and mean), SpO2. Routine treatment of the patients will be continued as per the Institute protocol. These patients will be assessed for the liver transplant free survival at 28 days and complications \[PHT related bleed, AKI, infections, HE\] within 90 days; transplant-free survival rate at 90 days; evolution of the AARC score for 2 wk.

Conditions

• Acute on Chronic Liver Failure

Interventions

Type	Name	Description
DRUG	Carvedilol 12.5 MG	Carvedilol 12.5 mg

Timeline

• Start date: 2022-01-07
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2022-01-06
• Last updated: 2022-01-11

Locations

1 site across 1 country: India